Economic benefits of inactivated influenza vaccines in the prevention of seasonal influenza in children

Salleras, L.; Navas, Encarna; Torner, Núria; Prat, A.; Garrido, P.; Soldevila, Núria; Domı́nguez, Àngela

doi:10.4161/hv.23269

Cited by 5 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 West Virginia, District of Columbia (DC), Virginia, North Carolina, Kentucky, Maryland, Delaware, Tennessee, South Carolina, Georgia, Florida, Alabama, Mississippi, Arkansas, Louisiana, Oklahoma, Texas. 4 Montana, Wyoming, Colorado, Utah, Idaho, Nevada, Washington, Oregon, California, Alaska, Hawaii, New Mexico, Arizona. 5 Includes Hawaii, where a prescription is required for pharmacist-administered influenza vaccination.…”

Section: Pharmacist-administered Pediatric Influenza Vaccination Ratesmentioning

confidence: 99%

Pharmacist-Administered Influenza Vaccination in Children and Corresponding Regulations

et al. 2022

View full text Add to dashboard Cite

In our retrospective cohort study, we evaluated trends in pharmacist-administered pediatric influenza vaccination rates in the United States and corresponding state-level pharmacist pediatric vaccination authorization models, including minimum age requirements, vaccination protocols, and/or prescription requirements. An administrative health claims database was used to capture influenza vaccinations in children less than 18 years old with 1 year of continuous enrollment and joinpoint regression was used to assess trends. Of the 3,937,376 pediatric influenza vaccinations identified over the study period, only 3.2% were pharmacist-administered (87.7% pediatrician offices, 2.3% convenience care clinics, 0.8% emergency care, and 6.0% other locations). Pharmacist-administered pediatric influenza vaccination was more commonly observed in older children (mean age 12.65 ± 3.26 years) and increased significantly by 19.2% annually over the study period (95% confidence interval 9.2%-30.2%, p < 0.05). The Northeast, with more restrictive authorization models, represented only 2.2% (n = 2816) of all pharmacist-administered pediatric influenza vaccinations. Utilization of pharmacist-administered pediatric influenza vaccination remains low. Providing children with greater access to vaccination with less restrictions may increase overall vaccination rates. Due to the COVID-19 pandemic and the Public Readiness and Emergency Preparedness Act, pharmacists will play a major role in vaccinating children.

show abstract

Section: Pharmacist-administered Pediatric Influenza Vaccination Ratesmentioning

confidence: 99%

Pharmacist-Administered Influenza Vaccination in Children and Corresponding Regulations

et al. 2022

View full text Add to dashboard Cite

show abstract

“…KENITAG further recommended pilot projects to generate additional local data to inform implementation of a nationwide influenza vaccination policy. In particular, KENITAG requested that local evidence be generated on influenza vaccine cost-effectiveness, because their recommendation largely relied on studies in non-African countries [ 4 – 6 ]. Given the cost implications of a nationwide programme, local economic evaluation data are needed to inform policy on the design and benefits of influenza vaccination in Kenya.…”

Section: Introductionmentioning

confidence: 99%

Seasonal influenza vaccination in Kenya: an economic evaluation using dynamic transmission modelling

Dawa

Emukule

Barasa

et al. 2020

BMC Med

View full text Add to dashboard Cite

Background: There is substantial burden of seasonal influenza in Kenya, which led the government to consider introducing a national influenza vaccination programme. Given the cost implications of a nationwide programme, local economic evaluation data are needed to inform policy on the design and benefits of influenza vaccination. We set out to estimate the cost-effectiveness of seasonal influenza vaccination in Kenya. Methods: We fitted an age-stratified dynamic transmission model to active surveillance data from patients with influenza from 2010 to 2018. Using a societal perspective, we developed a decision tree cost-effectiveness model and estimated the incremental cost-effectiveness ratio (ICER) per disability-adjusted life year (DALY) averted for three vaccine target groups: children 6-23 months (strategy I), 2-5 years (strategy II) and 6-14 years (strategy III) with either the Southern Hemisphere influenza vaccine (Strategy A) or Northern Hemisphere vaccine (Strategy B) or both (Strategy C: twice yearly vaccination campaigns, or Strategy D: year-round vaccination campaigns). We assessed cost-effectiveness by calculating incremental net monetary benefits (INMB) using a willingness-to-pay (WTP) threshold of 1-51% of the annual gross domestic product per capita ($17-$872). Results: The mean number of infections across all ages was 2-15 million per year. When vaccination was well timed to influenza activity, the annual mean ICER per DALY averted for vaccinating children 6-23 months ranged between $749

show abstract

Reticencia vacunal: una introducción conceptual

Salleras,

Toledo

et al. 2024

Vacunas

View full text Add to dashboard Cite

Economic benefits of inactivated influenza vaccines in the prevention of seasonal influenza in children

Cited by 5 publications

References 36 publications

Pharmacist-Administered Influenza Vaccination in Children and Corresponding Regulations

Pharmacist-Administered Influenza Vaccination in Children and Corresponding Regulations

Seasonal influenza vaccination in Kenya: an economic evaluation using dynamic transmission modelling

Reticencia vacunal: una introducción conceptual

Contact Info

Product

Resources

About